• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在中国人群中,循环 miR-29b 与非酒精性脂肪性肝病呈正相关。

Circulating miR-29b positively correlates with non-alcoholic fatty liver disease in a Chinese population.

机构信息

Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Department of General Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

J Dig Dis. 2019 Apr;20(4):189-195. doi: 10.1111/1751-2980.12716. Epub 2019 Apr 3.

DOI:10.1111/1751-2980.12716
PMID:30756471
Abstract

OBJECTIVE

Early screening of non-alcoholic fatty liver disease (NAFLD) is of great significance for the early detection and intervention in NAFLD. MicroRNAs (miRNAs) are important regulators of metabolic diseases including NAFLD. The aim of this study was to investigate the association of serum miR-29a-c with NAFLD in a Chinese population.

METHODS

Participants were divided into four groups based on the presence or absence of NAFLD and/or type 2 diabetes mellitus (T2DM). Quantitative polymerase chain reaction analysis was performed to quantify serum level of miR-29a-c. The association of miR-29a-c with NAFLD was evaluated.

RESULTS

Serum miR-29b, but not miR-29a or miR-29c, was positively associated with NAFLD (odds ratio [OR] 2.04 [1.16- 3.58], P = 0.013). Additionally, age, serum triglyceride and fasting plasma glucose (FPG) levels were independently associated with miR-29b (β ± standard error [SE] = 0.004 ± 0.002, P = 0.019 for age; β ± SE = 0.110 ± 0.054, P = 0.042 for triglyceride; and β ± SE = 0.389 ± 0.161, P = 0.016 for FPG). MiR-29b level was positively correlated with intrahepatic lipid content (β ± SE = 6.055 ± 2.630, P = 0.024) after adjusted for age, sex, and body mass index.

CONCLUSIONS

Serum miR-29b was associated with intrahepatic lipid content and NAFLD in a Chinese population-based study.

摘要

目的

非酒精性脂肪性肝病(NAFLD)的早期筛查对于 NAFLD 的早期发现和干预具有重要意义。微小 RNA(miRNA)是包括 NAFLD 在内的代谢性疾病的重要调节因子。本研究旨在探讨中国人群血清 miR-29a-c 与 NAFLD 的相关性。

方法

根据是否存在 NAFLD 和/或 2 型糖尿病(T2DM)将参与者分为四组。采用定量聚合酶链反应分析检测血清 miR-29a-c 水平。评估 miR-29a-c 与 NAFLD 的相关性。

结果

血清 miR-29b 与 NAFLD 呈正相关(优势比[OR]2.04[1.16-3.58],P=0.013),但 miR-29a 或 miR-29c 与 NAFLD 无关。此外,年龄、血清甘油三酯和空腹血糖(FPG)水平与 miR-29b 独立相关(β±标准误[SE]0.004±0.002,P=0.019 对年龄;β±SE0.110±0.054,P=0.042 对甘油三酯;β±SE0.389±0.161,P=0.016 对 FPG)。校正年龄、性别和体重指数后,miR-29b 水平与肝内脂质含量呈正相关(β±SE6.055±2.630,P=0.024)。

结论

在中国人群中,血清 miR-29b 与肝内脂质含量和 NAFLD 相关。

相似文献

1
Circulating miR-29b positively correlates with non-alcoholic fatty liver disease in a Chinese population.在中国人群中,循环 miR-29b 与非酒精性脂肪性肝病呈正相关。
J Dig Dis. 2019 Apr;20(4):189-195. doi: 10.1111/1751-2980.12716. Epub 2019 Apr 3.
2
Relationship between circulating miR-132 and non-alcoholic fatty liver disease in a Chinese population.在中国人群中循环 miR-132 与非酒精性脂肪性肝病的关系。
Hereditas. 2020 May 22;157(1):22. doi: 10.1186/s41065-020-00136-y.
3
Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).血清miR-29a和miR-122作为非酒精性脂肪性肝病(NAFLD)的潜在生物标志物
Microrna. 2018;7(3):215-222. doi: 10.2174/2211536607666180531093302.
4
Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals.血清 3-羧基-4-甲基-5-丙基-2-呋喃丙酸与脂质谱相关,可能对中国人的非酒精性脂肪性肝病有保护作用。
J Diabetes Investig. 2019 May;10(3):793-800. doi: 10.1111/jdi.12963. Epub 2018 Nov 28.
5
Decreased Serum miR-1296 may Serve as an Early Biomarker for the Diagnosis of Non-Alcoholic Fatty Liver Disease.血清miR-1296水平降低可能作为非酒精性脂肪性肝病诊断的早期生物标志物。
Clin Lab. 2019 Oct 1;65(10). doi: 10.7754/Clin.Lab.2019.190335.
6
Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者循环血清miR-34a和miR-122与血脂异常的关联
PLoS One. 2016 Apr 14;11(4):e0153497. doi: 10.1371/journal.pone.0153497. eCollection 2016.
7
Expression of PVT-1 and miR-29a/29b as reliable biomarkers for liver cirrhosis and their correlation with the inflammatory biomarkers profile.PVT-1 和 miR-29a/29b 的表达作为肝硬化可靠的生物标志物及其与炎症生物标志物谱的相关性。
Hum Exp Toxicol. 2024 Jan-Dec;43:9603271241251451. doi: 10.1177/09603271241251451.
8
Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population.循环 miR-20a、miR-27a 和 miR-126 与普通人群非酒精性脂肪性肝病的关联。
Sci Rep. 2019 Dec 11;9(1):18856. doi: 10.1038/s41598-019-55076-z.
9
Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.疾病特异性miR-34a作为中国人群非酒精性脂肪性肝炎的诊断标志物。
World J Gastroenterol. 2016 Nov 28;22(44):9844-9852. doi: 10.3748/wjg.v22.i44.9844.
10
Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.循环 microRNAs(miR-21、miR-34a、miR-122 和 miR-451)与非酒精性脂肪肝的关系。
Clin Chim Acta. 2013 Sep 23;424:99-103. doi: 10.1016/j.cca.2013.05.021. Epub 2013 May 30.

引用本文的文献

1
The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD.循环微小RNA在非酒精性脂肪性肝病的诊断、预后及个性化治疗中的应用
J Physiol Biochem. 2025 Jul 16. doi: 10.1007/s13105-025-01110-w.
2
Circulating microRNA panels in subjects with metabolic dysfunction-associated steatotic liver disease after following a 2-year dietary intervention.在进行为期2年的饮食干预后,代谢功能障碍相关脂肪性肝病患者的循环微RNA谱。
J Endocrinol Invest. 2025 Apr;48(4):987-1003. doi: 10.1007/s40618-024-02499-9. Epub 2024 Nov 16.
3
MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism.
微小RNA-337-3p通过调节糖脂代谢改善代谢相关脂肪性肝病。
iScience. 2023 Oct 28;26(11):108352. doi: 10.1016/j.isci.2023.108352. eCollection 2023 Nov 17.
4
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病无创生物标志物的进展
Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115.
5
Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD.非酒精性脂肪性肝病的临床和分子生物标志物用于诊断和分期。
Int J Mol Sci. 2021 Nov 2;22(21):11905. doi: 10.3390/ijms222111905.
6
Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease.血清细胞外囊泡中循环 microRNA-135a-3p 作为非酒精性脂肪性肝病潜在的生物学标志物。
Mol Med Rep. 2021 Jul;24(1). doi: 10.3892/mmr.2021.12137. Epub 2021 May 6.
7
Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.解析表观遗传修饰在脂肪性肝病中的作用:系统评价。
Eur J Clin Invest. 2021 May;51(5):e13479. doi: 10.1111/eci.13479. Epub 2021 Jan 4.
8
Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.非编码 RNA 在阿霉素诱导的心脏毒性中的作用及其作为生物标志物和治疗靶点的潜力。
Acta Pharmacol Sin. 2021 Apr;42(4):499-507. doi: 10.1038/s41401-020-0471-x. Epub 2020 Jul 21.
9
Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4.棕色脂肪组织移植通过靶向 NOX4 上调 miR-99a 改善糖尿病小鼠的肝脏代谢紊乱。
Adipocyte. 2020 Dec;9(1):57-67. doi: 10.1080/21623945.2020.1721970.